Passa al contenuto
Merck
Tutte le immagini(2)

Documenti fondamentali

G2167

Sigma-Aldrich

Gliclazide

powder, ≥98%

Sinonimo/i:

1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C15H21N3O3S
Numero CAS:
Peso molecolare:
323.41
Numero CE:
Numero MDL:
Codice UNSPSC:
12352125
ID PubChem:
NACRES:
NA.77

Livello qualitativo

Saggio

≥98%

Stato

powder

Colore

white

Punto di fusione

163-169 °C (lit.)

Solubilità

methylene chloride: soluble

Ideatore

Servier

Stringa SMILE

Cc1ccc(cc1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2

InChI

1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
BOVGTQGAOIONJV-UHFFFAOYSA-N

Informazioni sul gene

human ... KCNJ1(3758)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Gliclazide has been used:
  • to study its antiglycative properties and to study its effects on the glycation of bovine serum albumin (BSA) structure
  • as a reference standard in solid-phase extraction (SPE) followed by instrumental analysis using liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) for the quantification of water samples
  • to develop and validate a simple, sensitive, rapid, economic and isocratic high-performance liquid chromatography (HPLC) method for the determination of gliclazide

Used in the treatment of non-insulin dependent diabetes mellitus (NIDDM).

Azioni biochim/fisiol

Oxidative modification of low-density lipoprotein (LDL) plays an important role in vascular dysfunction associated with diabetes mellitus. Gliclazide is a second-generation sulfonylurea with free-radical-scavenging activity. Incubation of human aortic smooth muscle cell (HASMC) with native human LDL (100 μg/mL) in the presence of increasing concentrations of gliclazide (1 to 10 μg/mL) resulted in a dose-dependent decrease in HASMC-mediated LDL oxidation. Exposure of HASMCs to gliclazide (1 to 10 μg/mL) and native LDL (100 μg/mL) also led to a dose-dependent decrease in oxidized LDL-induced human monocyte adhesion to HASMCs. In addition, incubation of HASMCs with gliclazide dramatically reduced the ability of oxidized LDL to stimulate the proliferation of these cells. Finally, treatment of HASMCs with gliclazide resulted in a marked decrease in oxidatively modified LDL-induced monocyte chemoattractant protein (MCP)-1 and human heat shock protein 70 (HSP 70) expression, both at the gene and protein levels. These results show that gliclazide, at concentrations in the therapeutic range (5 to 10 μg/mL), is effective in vitro in reducing vascular smooth muscle cell (VSMC) dysfunction induced by oxidatively modified LDL. Administration of gliclazide to type 2 diabetic patients could form part of the strategy for the prevention and management of diabetic cardiovascular diseases

Caratteristiche e vantaggi

This compound was developed by Servier. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Exclamation mark

Avvertenze

Warning

Indicazioni di pericolo

Classi di pericolo

Acute Tox. 4 Oral

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 10

1 of 10

Glipizide Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1818

Glipizide

vibrant-m

BP366

Gliclazide impurity F

Chlorpropamide analytical standard, ≥97%

Supelco

C1290

Chlorpropamide

Glibenclamide ≥99% (HPLC)

Sigma-Aldrich

G0639

Glibenclamide

Tolbutamide analytical standard

Supelco

T0891

Tolbutamide

Captopril ≥98% (HPLC), powder

Sigma-Aldrich

C4042

Captopril

Ambroxolo analytical standard

Supelco

A9797

Ambroxolo

Azithromycin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1088

Azithromycin

Ewa Żurawska-Płaksej et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 189, 625-633 (2017-09-10)
Albumin, the major serum protein, plays a variety of functions, including binding and transporting endogenous and exogenous ligands. Its molecular structure is sensitive to different environmental modifiers, among which glucose is one of the most significant. In vivo albumin glycation
Ahmed Gedawy et al.
Journal of food and drug analysis, 27(1), 315-322 (2019-01-17)
An efficient and simple HPLC method has been developed and validated for the simultaneous determination of gliclazide and metformin hydrochloride in bulk and was applied on marketed metformin and gliclazide products. The mobile phase used for the chromatographic runs consisted
Dilipkumar Pal et al.
Drug delivery, 19(3), 123-131 (2012-02-23)
Novel tamarind seed polysaccharide (TSP)-alginate mucoadhesive microspheres were prepared using TSP and alginate as blend in different ratios with different calcium chloride (CaCl(2)) concentration as a cross linker by ionotropic gelation. The prepared microspheres were of spherical shape having rough
D N Juurlink et al.
Diabetic medicine : a journal of the British Diabetic Association, 29(12), 1524-1528 (2012-08-24)
Sulphonylureas promote insulin release by inhibiting pancreatic potassium channels. Older sulphonylureas such as glyburide (glibenclamide), but not newer ones such as gliclazide, antagonize similar channels in myocardium, interfering with the protective effects of ischaemic preconditioning. Whether this imparts a higher
Nils E Magnusson et al.
Basic & clinical pharmacology & toxicology, 111(4), 254-261 (2012-05-31)
Sulphonylureas (SUs) used in the treatment for type 2 diabetes have been shown to result in different clinical outcome. This study hypothesized that three widely used SUs, glibenclamide, glimepiride and gliclazide, may affect function and survival of insulin-producing cells differently.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.